BioCryst Pharmaceuticals Dirección
Dirección controles de criterios 3/4
El CEO de BioCryst Pharmaceuticals' es Jon Stonehouse , nombrado en Jan 2007, tiene una permanencia de 17.25 años. compensación anual total es $6.98M, compuesta por 9.2% salario y 90.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.41% de las acciones de la empresa, por valor de $3.54M. La antigüedad media del equipo directivo y de la junta directiva es de 4.3 años y 4.7 años, respectivamente.
Información clave
Jon Stonehouse
Chief Executive Officer (CEO)
US$4.8m
Compensación total
Porcentaje del salario del CEO | 13.9% |
Permanencia del CEO | 17.3yrs |
Participación del CEO | 0.4% |
Permanencia media de la dirección | 4.2yrs |
Promedio de permanencia en la Junta Directiva | 4.8yrs |
Actualizaciones recientes de la dirección
Recent updates
BioCryst: Estimate-Beating Q1 But Risks Are Considerable
May 07Insufficient Growth At BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hampers Share Price
Apr 29BioCryst's Revenue Gains Offset By Rising Expenses: A Closer Look
Feb 27BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking After Shares Rocket 34%
Jan 09BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares Lagging The Industry But So Is The Business
Jun 08BioCryst Pharmaceuticals: Working To Increase Market Presence Of Orladeyo
Oct 11BioCryst Pharmaceuticals promotes Sheridan to development chief
Sep 14BioCryst wins FDA’s Orphan Drug status for bone disorder therapy
Aug 31BioCryst to supply 10K doses of influenza drug Rapivab to US for ~$7M
Aug 25BioCryst Orladeyo gets approval in Saudi Arabia to prevent hereditary angioedema attacks
Aug 18BioCryst Pharmaceuticals Q2 2022 Earnings Preview
Aug 03BioCryst Pharmaceuticals: Waiting For Clarity
Jul 25BioCryst: A Prudent Diversification
Jun 24BioCryst: BCX9930's Hiccup Affects The Entire Company
Apr 11Análisis de compensación del CEO
Fecha | Compensación total | Salario | Ingresos de la empresa |
---|---|---|---|
Mar 31 2024 | n/a | n/a | -US$209m |
Dec 31 2023 | US$5m | US$666k | -US$227m |
Sep 30 2023 | n/a | n/a | -US$236m |
Jun 30 2023 | n/a | n/a | -US$243m |
Mar 31 2023 | n/a | n/a | -US$226m |
Dec 31 2022 | US$7m | US$640k | -US$247m |
Sep 30 2022 | n/a | n/a | -US$193m |
Jun 30 2022 | n/a | n/a | -US$210m |
Mar 31 2022 | n/a | n/a | -US$194m |
Dec 31 2021 | US$7m | US$583k | -US$184m |
Sep 30 2021 | n/a | n/a | -US$227m |
Jun 30 2021 | n/a | n/a | -US$214m |
Mar 31 2021 | n/a | n/a | -US$209m |
Dec 31 2020 | US$6m | US$567k | -US$183m |
Sep 30 2020 | n/a | n/a | -US$125m |
Jun 30 2020 | n/a | n/a | -US$116m |
Mar 31 2020 | n/a | n/a | -US$115m |
Dec 31 2019 | US$2m | US$550k | -US$109m |
Sep 30 2019 | n/a | n/a | -US$134m |
Jun 30 2019 | n/a | n/a | -US$126m |
Mar 31 2019 | n/a | n/a | -US$107m |
Dec 31 2018 | US$4m | US$550k | -US$101m |
Sep 30 2018 | n/a | n/a | -US$93m |
Jun 30 2018 | n/a | n/a | -US$79m |
Mar 31 2018 | n/a | n/a | -US$77m |
Dec 31 2017 | US$4m | US$533k | -US$66m |
Compensación vs. Mercado: La compensación total de Jon($USD6.98M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.44M).
Compensación vs. Ingresos: La compensación de Jon ha sido consistente con los resultados de la empresa en el último año.
CEO
Jon Stonehouse (62 yo)
17.3yrs
Permanencia
US$4,777,778
Compensación
Mr. Jon P. Stonehouse has been the Chief Executive Officer and Executive Director of BioCryst Pharmaceuticals, Inc. at Shionogi & Co. Ltd. since joining in January 8, 2007 and also has been its President s...
Equipo directivo
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
CEO, President & Executive Director | 17.3yrs | US$4.78m | 0.41% $ 4.6m | |
Senior VP | 4.1yrs | US$1.79m | 0.065% $ 715.3k | |
Senior VP | 17.7yrs | US$1.93m | 0.087% $ 958.2k | |
Chief Research & Development Officer | 3.2yrs | US$2.39m | 0.040% $ 447.0k | |
Senior VP & Chief Commercial Officer | 4.3yrs | US$1.74m | 0.086% $ 954.3k | |
Chief Communications Officer | no data | sin datos | sin datos | |
Chief People Officer | no data | sin datos | sin datos | |
Chief Development Officer & Interim Chief Medical Officer | 15.8yrs | US$2.66m | 0% $ 0 | |
Chief Discovery Officer | 10.6yrs | US$2.57m | 0% $ 0 | |
Chief Data & Insights Officer | 2.5yrs | sin datos | sin datos | |
Chief Strategy Officer | 1.7yrs | sin datos | sin datos | |
Chief Business Development Officer | 1.3yrs | sin datos | sin datos |
4.2yrs
Permanencia media
56yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de BCRX se considera experimentado (4.3 años antigüedad media).
Miembros de la Junta
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
CEO, President & Executive Director | 17.3yrs | US$4.78m | 0.41% $ 4.6m | |
Independent Director | 2.8yrs | US$434.82k | 0.017% $ 188.9k | |
Independent Director | 5.3yrs | US$446.90k | 0.023% $ 249.8k | |
Independent Director | 4.3yrs | US$434.54k | 0.0099% $ 109.1k | |
Independent Director | 12.6yrs | US$432.74k | 0.0062% $ 68.9k | |
Independent Director | 5.4yrs | US$433.57k | 0.017% $ 188.2k | |
Independent Chair | 12.3yrs | US$470.30k | 0.032% $ 348.8k | |
Independent Director | 2.7yrs | US$424.40k | 0.0062% $ 68.9k | |
Independent Director | 2.3yrs | US$423.15k | 0.0043% $ 47.6k | |
Independent Director | 2.7yrs | US$422.32k | 0.0062% $ 68.9k |
4.8yrs
Permanencia media
62.5yo
Promedio de edad
Junta con experiencia: La junta directiva de BCRX se considera experimentada (4.7 años de antigüedad promedio).